Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs
- 24 November 2009
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 13 (1) , 90-98
Abstract
(2010). Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. Journal of Medical Economics: Vol. 13, No. 1, pp. 90-98. doi: 10.3111/13696990903579501Keywords
This publication has 16 references indexed in Scilit:
- Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing dosesPharmacoepidemiology and Drug Safety, 2008
- Adherence to interferon-beta treatment and results of therapy switchingJournal of the Neurological Sciences, 2007
- Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis populationCurrent Medical Research and Opinion, 2007
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006
- Treatment optimisation in multiple sclerosisNeurological Sciences, 2005
- Interrupted therapyNeurology, 2003
- Multiple sclerosisMedical Clinics of North America, 2003
- Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trialsAnnals of Neurology, 2002
- Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]Neurology, 2002
- A comprehensive assessment of the cost of multiple sclerosis in the United StatesMultiple Sclerosis Journal, 1998